498 related articles for article (PubMed ID: 22773753)
21. How does the Schwann cell lineage form tumors in NF1?
Carroll SL; Ratner N
Glia; 2008 Nov; 56(14):1590-1605. PubMed ID: 18803326
[TBL] [Abstract][Full Text] [Related]
22. Mouse tumor model for neurofibromatosis type 1.
Vogel KS; Klesse LJ; Velasco-Miguel S; Meyers K; Rushing EJ; Parada LF
Science; 1999 Dec; 286(5447):2176-9. PubMed ID: 10591653
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1.
Wolman MA; de Groh ED; McBride SM; Jongens TA; Granato M; Epstein JA
Cell Rep; 2014 Sep; 8(5):1265-70. PubMed ID: 25176649
[TBL] [Abstract][Full Text] [Related]
24. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
25. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.
Rutkowski JL; Wu K; Gutmann DH; Boyer PJ; Legius E
Hum Mol Genet; 2000 Apr; 9(7):1059-66. PubMed ID: 10767330
[TBL] [Abstract][Full Text] [Related]
26. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
27. Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis.
Miller SJ; Li H; Rizvi TA; Huang Y; Johansson G; Bowersock J; Sidani A; Vitullo J; Vogel K; Parysek LM; DeClue JE; Ratner N
Mol Cell Biol; 2003 Mar; 23(6):2213-24. PubMed ID: 12612091
[TBL] [Abstract][Full Text] [Related]
28. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
29. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in neurofibromatosis type 1.
Arun D; Gutmann DH
Curr Opin Neurol; 2004 Apr; 17(2):101-5. PubMed ID: 15021234
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.
Carroll SL; Stonecypher MS
J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of neurofibromatosis type 1.
Korf BR
Curr Neurol Neurosci Rep; 2001 Mar; 1(2):162-7. PubMed ID: 11898512
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
[TBL] [Abstract][Full Text] [Related]
35. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.
Keng VW; Rahrmann EP; Watson AL; Tschida BR; Moertel CL; Jessen WJ; Rizvi TA; Collins MH; Ratner N; Largaespada DA
Cancer Res; 2012 Jul; 72(13):3405-13. PubMed ID: 22700876
[TBL] [Abstract][Full Text] [Related]
36. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.
Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N
Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.
Bai RY; Esposito D; Tam AJ; McCormick F; Riggins GJ; Wade Clapp D; Staedtke V
Gene Ther; 2019 Jun; 26(6):277-286. PubMed ID: 31127187
[TBL] [Abstract][Full Text] [Related]
38. Mouse models of neurofibromatosis 1 and 2.
Gutmann DH; Giovannini M
Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
[TBL] [Abstract][Full Text] [Related]
39. Neurofibromatosis type 1.
Cimino PJ; Gutmann DH
Handb Clin Neurol; 2018; 148():799-811. PubMed ID: 29478615
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
